Teresa Marie Nygren

Mrs. Teresa Marie Nygren

Robert Koch Institute, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2019 in Pathogens
Verified
Journal Article
Open access
PDF file
WHWiebke Hellenbrand
Wiebke Hellenbrand
TNTeresa Marie Nygren
Teresa Marie Nygren
MBMerle Margarete Böhmer
Merle Margarete Böhmer
CWChristiane Wagner-Wiening
Christiane Wagner-Wiening
GDGerhard Dobbler
Gerhard Dobbler
DADoris Altmann
Doris Altmann
We reviewed tick-borne encephalitis (TBE) surveillance and epidemiology in Germany, as these underlie public health recommendations, foremost vaccination. We performed descriptive analyses of notification data (2001–2018, n = 6063) according to region, demographics and clinical manifestations and calculated incidence trends using negative binomial regression. Risk areas were defined based on incidence in administrative districts. Most cases (89%) occurred in the federal states of Baden-Wurttemberg and Bavaria, where annual TBE incidence fluctuated markedly between 0.7–2.0 cases/100,000 inhabitants. A slight but significantly increasing temporal trend was observed from 2001–2018 (age-adjusted incidence rate ratio (IRR) 1.02 (95% confidence interval (CI): 1.01–1.04)), primarily driven by high case numbers in 2017–2018. Mean incidence was highest in 40–69-year-olds and in males. More males (23.7%) than females (18.0%, p = 0.02) had severe disease (encephalitis or myelitis), which increased with age, as did case-fatality (0.4% overall; 2.1% among ≥70-year-olds). Risk areas increased from 129 districts in 2007 to 161 in 2019. Expansion occurred mainly within existent southern endemic areas, with slower contiguous north-eastern and patchy north-western spread. Median vaccination coverage at school entry in risk areas in 2016–2017 ranged from 20%–41% in 4 states. Increasing TBE vaccine uptake is an urgent priority, particularly in high-incidence risk areas.

16 March 2023 in Eurosurveillance
Verified
Journal Article
Open access
JHJasper Van Heuverswyn
Jasper Van Heuverswyn
LHLuisa K. Hallmaier-Wacker
Luisa K. Hallmaier-Wacker
JBJulien Beauté
Julien Beauté
JDJoana Gomes Dias
Joana Gomes Dias
JHJoana M Haussig
Joana M Haussig
CGCéline Marie Elise Gossner
Céline Marie Elise Gossner
Background: Tick-borne encephalitis (TBE) is a vaccine-preventable disease involving the central nervous system. TBE became a notifiable disease on the EU/EEA level in 2012. Aim: We aimed to provide an updated epidemiological assessment of TBE in the EU/EEA, focusing on spatiotemporal changes. Methods: We performed a descriptive analysis of case characteristics, time and location using data of human TBE cases reported by EU/EEA countries to the European Centre for Disease Prevention and Control with disease onset in 2012–2020. We analysed data at EU/EEA, national, and subnational levels and calculated notification rates using Eurostat population data. Regression models were used for temporal analysis. Results: From 2012 to 2020, 19 countries reported 29,974 TBE cases, of which 24,629 (98.6%) were autochthonous. Czechia, Germany and Lithuania reported 52.9% of all cases. The highest notification rates were recorded in Lithuania, Latvia, and Estonia (16.2, 9.5 and 7.5 cases/100,000 population, respectively). Fifty regions from 10 countries, had a notification rate ≥ 5/100,000. There was an increasing trend in number of cases during the study period with an estimated 0.053 additional TBE cases every week. In 2020, 11.5% more TBE cases were reported than predicted based on data from 2016 to 2019. A geographical spread of cases was observed, particularly in regions situated north-west of known endemic regions. Conclusion: A close monitoring of ongoing changes to the TBE epidemiological situation in Europe can support the timely adaption of vaccination recommendations. Further analyses to identify populations and geographical areas where vaccination programmes can be of benefit are needed.

14 February 2023 in Journal of Infection
Verified
Journal Article
Closed access
TNTeresa Marie Nygren
Teresa Marie Nygren
APAntonia Pilic
Antonia Pilic
MBMerle M. Böhmer
Merle M. Böhmer
CWChristiane Wagner-Wiening
Christiane Wagner-Wiening
SWSimone-Beatrice Went
Simone-Beatrice Went
WHWiebke Hellenbrand
Wiebke Hellenbrand

21 November 2019 in Eurosurveillance
Verified
Journal Article
Open access
TNTeresa Marie Nygren
Teresa Marie Nygren
MHMaya Holding
Maya Holding
RHRoger Hewson
Roger Hewson
THThomas Harder
Thomas Harder
JMJolyon M Medlock
Jolyon M Medlock
OWOle Wichmann
Ole Wichmann
The United Kingdom (UK) has thus far been considered to be free from tick-borne encephalitis (TBE), yet in July 2019, a German infant developed serologically diagnosed TBE following a tick bite in southern England. This first report of a probable human case together with recent findings of TBE virus in ticks in foci in England suggest that TBE may be acquired in parts of England and should be considered in patients with aetiologically-unexplained neurological manifestations.

9 July 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TNTeresa Marie Nygren
Teresa Marie Nygren
APAntonia Pilic
Antonia Pilic
MBMerle Margarete Böhmer
Merle Margarete Böhmer
CWChristiane Wagner-Wiening
Christiane Wagner-Wiening
OWOle Wichmann
Ole Wichmann
WHWiebke Hellenbrand
Wiebke Hellenbrand
Tick-borne encephalitis (TBE) vaccination coverage remains low in Germany. Our case–control study (2018–2020) aimed to examine reasons for low vaccine uptake, vaccine effectiveness (VE), and vaccine breakthrough infections (VBIs). Telephone interviews (581 cases, 975 matched controls) covered vaccinations, vaccination barriers, and confounders identified with directed acyclic graphs. Multivariable logistic regression determined VE as 1—odds ratio with 95% confidence intervals (CI). We additionally calculated VE with the Screening method using routine surveillance and vaccination coverage data. Main vaccination barriers were poor risk perception and fear of adverse events. VE was 96.6% (95% CI 93.7–98.2) for ≥ 3 doses and manufacturer-recommended dosing intervals. Without boosters, VE after ≥ 3 doses at ≤ 10 years was 91.2% (95% CI 82.7–95.6). VE was similar for homologous/heterologous vaccination. Utilising routine surveillance data, VE was comparable (≥ 3 doses: 92.8%). VBIs (n = 17, 2.9% of cases) were older, had more comorbidities and higher severity than unvaccinated cases. However, only few VBIs were diagnostically confirmed; 57% of re-tested vaccinated cases (≥ 1 dose, n = 54) proved false positive. To increase TBE vaccine uptake, communication efforts should address complacency and increase confidence in the vaccines’ safety. The observed duration of high VE may inform decision-makers to consider extending booster intervals to 10 years.

6 April 2023 in Infection
Verified
Journal Article
Open access
PDF file
TNTeresa Marie Nygren
Teresa Marie Nygren
APAntonia Pilic
Antonia Pilic
MBMerle Margarete Böhmer
Merle Margarete Böhmer
CWChristiane Wagner-Wiening
Christiane Wagner-Wiening
OWOle Wichmann
Ole Wichmann
WHWiebke Hellenbrand
Wiebke Hellenbrand
Purpose: Despite being vaccine-preventable, tick-borne encephalitis (TBE) continues to cause considerable morbidity in Germany. Limited insight into potentially debilitating consequences of TBE may partially underly low (~ 20%) TBE vaccine uptake. We aimed to systematically assess TBE sequelae and other consequences. Methods: Routinely notified TBE patients from 2018 to 2020 from Southern Germany were invited to telephone interviews acutely and again after 18 months. Duration of acute symptoms was prospectively assessed. Recovery was defined as score 0 on the modified RANKIN scale. Determinants of time to recovery were analysed with cox regression, adjusted for covariates identified using directed acyclic graphs, yielding hazard ratios (HR) and 95% confidence intervals (CI). Results: Of 558 cases, 523 (93.7%) completed follow-up. Full recovery was reported by 67.3% (children: 94.9%, adults: 63.8%). Sequelae included fatigue (17.0%), weakness (13.4%), concentration deficit (13.0%), and impaired balance (12.0%). Compared with 18–39-year-olds, recovery rates were 44% lower in ≥ 50-year-olds (HR: 0.56, 95%CI 0.42–0.75) and 79% higher in children (HR: 1.79, 95%CI 1.25–2.56). The recovery rate was 64% lower after severe TBE (compared to mild; HR: 0.36, 95%CI 0.25–0.52) and 22% lower with comorbidities (HR: 0.78, 95%CI 0.62–0.99). Substantial health-care use was reported (90.1% hospitalisation, 39.8% rehabilitation). Of employed cases, 88.4% required sick leave; 10.3% planned/reported premature retirement due to sequelae. Conclusion: Half the adult and 5% of paediatric patients reported persisting sequelae after 18 months. Improved prevention could alleviate both individual (morbidity) and societal TBE burden (health-care costs, productivity losses). Insights into sequelae can help guide at-risk populations towards tick-avoidant strategies and encourage TBE vaccination.